Harlan S. Robins Sells 3,895 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Co. (NASDAQ:ADPT) insider Harlan S. Robins sold 3,895 shares of the company’s stock in a transaction on Monday, July 19th. The shares were sold at an average price of $37.12, for a total transaction of $144,582.40. Following the sale, the insider now owns 73,255 shares of the company’s stock, valued at $2,719,225.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Adaptive Biotechnologies stock opened at $38.18 on Thursday. The firm’s fifty day moving average is $37.75. The stock has a market cap of $5.36 billion, a P/E ratio of -33.20 and a beta of 0.28. Adaptive Biotechnologies Co. has a 12-month low of $30.41 and a 12-month high of $71.25.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.12. The business had revenue of $38.44 million for the quarter, compared to the consensus estimate of $28.53 million. Adaptive Biotechnologies had a negative net margin of 134.12% and a negative return on equity of 22.42%. As a group, analysts predict that Adaptive Biotechnologies Co. will post -1.55 earnings per share for the current fiscal year.

ADPT has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Tuesday. Morgan Stanley lowered their price target on shares of Adaptive Biotechnologies from $60.00 to $55.00 and set an “equal weight” rating for the company in a report on Friday, May 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Adaptive Biotechnologies has a consensus rating of “Buy” and an average price target of $59.20.

A number of institutional investors have recently modified their holdings of ADPT. Credit Suisse AG increased its position in Adaptive Biotechnologies by 4.5% during the 4th quarter. Credit Suisse AG now owns 69,988 shares of the company’s stock valued at $4,139,000 after purchasing an additional 2,995 shares during the period. Public Employees Retirement System of Ohio grew its position in shares of Adaptive Biotechnologies by 33.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 40,092 shares of the company’s stock worth $2,371,000 after buying an additional 10,028 shares during the period. LPL Financial LLC purchased a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth about $278,000. Federated Hermes Inc. grew its position in shares of Adaptive Biotechnologies by 43.1% in the 4th quarter. Federated Hermes Inc. now owns 60,088 shares of the company’s stock worth $3,553,000 after buying an additional 18,088 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Adaptive Biotechnologies by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 551,426 shares of the company’s stock worth $32,606,000 after buying an additional 10,575 shares during the period. 80.48% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Featured Story: Percentage Gainers

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.